<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-133076" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ocular Futility and End of Sight Care</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ponnusamy</surname>
            <given-names>Vikram E.</given-names>
          </name>
          <aff>University of North Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Alice Y.</given-names>
          </name>
          <aff>University of North Carolina- Chapel Hill</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikram Ponnusamy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alice Zhang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-133076.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Ocular futility addresses situations in which the risks of treatment vastly outweigh the benefits of treatment. End-stage ocular conditions include severe trauma, advanced age-related macular degeneration, end-stage glaucoma, and other disease processes where intervention offers limited potential benefit. Determining when intervention is futile is difficult. Therefore, critical ethical principles, including beneficence, nonmaleficence, and autonomy, must always be considered. This activity reviews the determination of ocular futility and highlights the role of the healthcare team in managing patients with end-stage ocular conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the end-stage ocular conditions that commonly lead to ocular futility.</p></list-item><list-item><p>Employ best practices when obtaining a comprehensive medical history and performing a physical examination to identify factors that may indicate the potential futility of further ocular interventions.</p></list-item><list-item><p>Apply the ethical principles of beneficence, nonmaleficence, and autonomy when counseling patients with end-stage ocular disorders about ocular futility.</p></list-item><list-item><p>Develop and effectively apply interprofessional team processes to facilitate care for patients who may be deemed ocularly futile.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133076&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133076">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-133076.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Ocular futility is the point at which therapeutic interventions are no longer a net benefit for the patient. Determining the point at which the further treatment of ocular pathology is futile is challenging. Medical futility is well-described in many other areas of medicine. When considering the patient's physical, mental, and emotional health,&#x000a0;healthcare professionals use medical futility to aid in their decision not to treat a patient because available therapeutic interventions will likely not achieve a benefit. Withholding patient care is an ethically challenging situation. For many conditions, the threshold where further treatment would be considered futile is variable, depending on the healthcare practitioner.</p>
        <p>In ophthalmology, there are no strict boundaries for when&#x000a0;continued therapy is considered futile. Generally, when vision decreases to no light perception, the priority of ocular care switches from saving vision to comfort and cosmesis. However, practitioners use no&#x000a0;strict visual acuity cut-off when deciding to withhold further intervention that may present extensive risk. For example, a patient with end-stage advanced age-related macular degeneration may have no visual acuity benefit to continuing&#x000a0;regular intravitreal anti-vascular endothelial growth factor (VEGF) injections. Intravitreal injections present a rare but severe risk of endophthalmitis and burden the patient and their caregivers by requiring regular appointments.<xref ref-type="bibr" rid="article-133076.r1">[1]</xref></p>
      </sec>
      <sec id="article-133076.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Ocular futility can be applied to many aspects of ophthalmologic care.</p>
        <p>
<bold>Ocular Trauma</bold>
</p>
        <p>Severe ocular trauma resulting in an open globe injury can have a guarded prognosis. The ocular trauma score can be utilized to predict outcomes following globe repair.<xref ref-type="bibr" rid="article-133076.r2">[2]</xref>&#x000a0;However, regardless of the ocular trauma score, a common practice is to close the globe as soon as possible. Patients with severe globe injuries who undergo primary globe closure are frequently subjected to an enucleation or evisceration procedure within the following days; studies indicate that 10% to 30% of patients have secondary enucleation. The decision to undergo primary enucleation is difficult; many patients with severe ocular injury may&#x000a0;be unable to consent, and the psychological burden of removing an eye may be too great in the acute setting.<xref ref-type="bibr" rid="article-133076.r3">[3]</xref><xref ref-type="bibr" rid="article-133076.r4">[4]</xref>&#x000a0;In the setting of severe ocular trauma, it can be difficult to determine if it is best to have one less procedure or attempt primary closure.</p>
        <p>
<bold>Advanced Age-related Macular Degeneration (ARMD)</bold>
</p>
        <p>Advanced ARMD is the presence of geographic atrophy or a choroidal neovascular membrane (CNVM). No currently available treatment reverses nonexudative ARMD; geographic atrophy is permanent. However, exudative ARMD is frequently treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections. While the early treatment of CNVM yields excellent visual benefits, as ARMD progresses, the&#x000a0;accumulation of atrophy or subfoveal fibrosis&#x000a0;inevitably leads to permanent vision loss.<xref ref-type="bibr" rid="article-133076.r5">[5]</xref> The timeline and severity of disease progression are highly variable between patients.</p>
        <p>The benefit of continued injections is questionable in patients with neovascular ARMD with a significant atrophic component. One retrospective study suggested that continuing anti-VEGF injections after achieving morphologic and functional stability does not necessarily prevent future exudative changes.<xref ref-type="bibr" rid="article-133076.r6">[6]</xref> This raises the question of when to stop injections, which has no clear answer in the literature.&#x000a0;The general practice is to stop anti-VEGF injections when there is a sizeable disciform scar, even if there is a recurrence of fluid or subretinal hemorrhage. However, individual ophthalmologists may differ in their approach.</p>
        <p>
<bold>Strabismus Surgery in a Terminally Ill Child</bold>
</p>
        <p>Strabismus surgery in children is important for reestablishing binocular vision and improving appearance. Although surgery to improve appearance&#x000a0;could be&#x000a0;categorized as a cosmetic procedure, the importance of appearance on psychosocial development has been highlighted in many studies.<xref ref-type="bibr" rid="article-133076.r7">[7]</xref><xref ref-type="bibr" rid="article-133076.r8">[8]</xref><xref ref-type="bibr" rid="article-133076.r9">[9]</xref> However, determining whether to pursue this type of surgery on a child with a terminal condition is challenging. One case study argues that strabismus surgery is not futile if parents request it, even if the child is terminally ill. The authors of this case study argue that performing the procedure aided the parents in accepting the terminal condition of the child.<xref ref-type="bibr" rid="article-133076.r10">[10]</xref>&#x000a0;While this case report&#x000a0;raises the important point of family-centered care, deciding to perform such a procedure on a terminally ill child is difficult.&#x000a0;</p>
        <p>
<bold>Advanced Glaucoma</bold>
</p>
        <p>In patients with advanced glaucoma, great efforts are taken to save the last remnants of vision and the visual field. In the most conservative situations, patients with advanced glaucoma are subjected to rigorous drop regimens that&#x000a0;place a significant treatment burden on the patient or caregiver and have ocular or systemic adverse effects.&#x000a0;These combined barriers frequently lead to therapeutic noncompliance.&#x000a0;</p>
        <p>Patients with advanced glaucoma can also be treated with incisional glaucoma surgery. While minimally invasive glaucoma surgery is gaining popularity, traditional tube shunts and trabeculectomy are typical for advanced glaucoma. These surgeries come with a host of potential complications, as the general framework of each procedure is to establish an opening into the eye, which increases the risk of infection, hypotony, and choroidal&#x000a0;effusions. In patients with glaucoma refractory to the prior treatments, transscleral cyclophotocoagulation is used, but this procedure comes with its own risk, including a 13% to 50% risk of vision loss.<xref ref-type="bibr" rid="article-133076.r11">[11]</xref><xref ref-type="bibr" rid="article-133076.r12">[12]</xref>&#x000a0;</p>
        <p>In a patient with persistently elevated eye pressures with only a central island of vision remaining, providing the most efficacious intraocular pressure (IOP) lowering treatment may seem like the best option. However, the decision is not usually straightforward, and considering potential complications and patient goals is critical. The lack of a thorough understanding of the pathophysiology of glaucoma further complicates these decisions; IOP is currently the only known modifiable risk factor for glaucoma, and every current therapy focuses on IOP reduction. Despite these interventions, many landmark glaucoma trials have demonstrated disease progression in a small percentage of patients despite a good reduction in IOP.<xref ref-type="bibr" rid="article-133076.r13">[13]</xref><xref ref-type="bibr" rid="article-133076.r14">[14]</xref><xref ref-type="bibr" rid="article-133076.r15">[15]</xref></p>
        <p>
<bold>Advanced Neurotrophic Keratopathy</bold>
</p>
        <p>Neurotrophic keratopathy is most commonly&#x000a0;due to a herpetic viral infection. Other causes include&#x000a0;topical anesthetic or drop toxicity, burns, chemical injury, contact lens abuse, radiation exposure, and corneal surgery. Neurotrophic keratopathy is challenging to treat; without proper innervation, the cornea loses its ability to maintain its structure and heal wounds. Advanced or stage 3 neurotrophic keratopathy is characterized by corneal ulcers, melting, and perforation. Once the cornea reaches this stage, treatment is limited and corneal transplants do not survive. Without the protective factors provided by innervation, transplanted tissue succumbs to ulceration&#x000a0;and melts.<xref ref-type="bibr" rid="article-133076.r16">[16]</xref>&#x000a0;</p>
        <p>Advanced neurotrophic keratopathy frequently requires invasive treatments such as conjunctival flaps&#x000a0;and temporary or permanent tarsorrhaphies.<xref ref-type="bibr" rid="article-133076.r17">[17]</xref>&#x000a0;The decision to perform these procedures is difficult for patients and surgeons alike. These procedures may block the visual axis, preventing the eye from seeing. Although&#x000a0;conjunctival flaps and tarsorrhaphies are reversible, deciding if and when to undergo reversal is also challenging, as corneal health may be unchanged. Promising new therapeutic interventions, such as neurotization surgery, are only performed at select tertiary care centers.<xref ref-type="bibr" rid="article-133076.r18">[18]</xref></p>
      </sec>
      <sec id="article-133076.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In Denmark, in 2010, the incidence of legal blindness from ARMD was 25.7 per 100,000, an approximate 50% decrease since 2000.<xref ref-type="bibr" rid="article-133076.r19">[19]</xref>&#x000a0;</p>
        <p>In the United States,&#x000a0;27% of eyes with severe ocular trauma developed legal blindness.<xref ref-type="bibr" rid="article-133076.r20">[20]</xref>&#x000a0;Another study quoted that 35% of eyes with severe ocular trauma developed visual acuity &#x0003c;20/200.<xref ref-type="bibr" rid="article-133076.r21">[21]</xref>&#x000a0;</p>
        <p>Primary open-angle glaucoma&#x000a0;affects&#x000a0;approximately 2% of&#x000a0;people over 40 years of age, and the&#x000a0;prevalence&#x000a0;increases with age.<xref ref-type="bibr" rid="article-133076.r22">[22]</xref>&#x000a0;It is difficult for patients with primary open-angle glaucoma to recognize a problem before significant permanent optic nerve damage exists.&#x000a0;An Early Manifest Glaucoma Trial screening study identified that 30% of patients&#x000a0;with&#x000a0;newly diagnosed glaucoma had severe-stage disease in at least one eye.<xref ref-type="bibr" rid="article-133076.r23">[23]</xref></p>
        <p>The incidence of neurotrophic keratopathy is 1 to 5 per 10,000. The results of one study&#x000a0;revealed that&#x000a0;30% of eyes with neurotrophic keratopathy required penetrating keratoplasty, 33% of which required&#x000a0;multiple transplants&#x000a0;within 1 year.<xref ref-type="bibr" rid="article-133076.r24">[24]</xref></p>
      </sec>
      <sec id="article-133076.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Ocular futility describes the state at which further treatment of an ocular disease&#x000a0;produces no additional benefit to the patient. Ocular futility is most commonly encountered&#x000a0;in ocular diseases with poor visual outcomes. However, ocular futility can also be a consideration for patients with poor life expectancy who may not benefit from an ophthalmic intervention.</p>
      </sec>
      <sec id="article-133076.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In the context of ocular futility, several factors need to be considered in evaluating and managing patients with certain ocular conditions.</p>
        <p>Historical factors include a history of congenital or systemic diseases associated with poor life expectancy, ocular trauma, and other debilitating systemic conditions that hinder proper ocular care, such as advanced dementia. Additionally, caregiver or patient fatigue resulting from frequent appointments and a lack of improvement despite therapy should also be considered. Furthermore, poor initial visual acuity and significantly elevated intraocular pressure can serve as important physical examination findings indicating the need for careful consideration of the potential futility of further ocular interventions.</p>
        <p>In patients with advanced ARMD, disciform scarring or fibrosis involving the fovea or subfoveal geographic atrophy may indicate continued intervention's futility. In severe ocular trauma, expulsed intraocular contents or a penetrating or perforating injury of the posterior chamber that extends more than 5 mm behind the limbus may indicate further ocular futility. A pale optic nerve head or large cup-disc ratio in advanced glaucoma may preclude the benefit of further treatment. Patients with neurotrophic keratopathy who demonstrate dense band keratopathy, corneal vascularization or edema, subepithelial or stromal infiltrates, or corneal thinning or ulceration may have reached the limits of ocular therapy.</p>
      </sec>
      <sec id="article-133076.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Imaging studies may prove helpful in evaluating the ocular futility of some disease processes.</p>
        <p>In patients with advanced ARMD, optical coherence tomography (OCT) of the macula&#x000a0;that reveals&#x000a0;complete subfoveal effacement of the ellipsoid zone band or significant subfoveal fibrosis in the case of a disciform scar indicates advanced and irreversible damage to the macula, suggesting limited potential for visual improvement with interventions.</p>
        <p>OCT of the retinal nerve fiber layer in patients with advanced glaucoma that reveals diffuse thinning of the optic nerve head and visual field testing that demonstrates a significantly decreased mean deviation or a very small island of the visual field indicates severe and irreversible damage to the optic nerve, predicting a poor prognosis for visual recovery despite continued interventions.</p>
        <p>In patients with severe ocular trauma, computed tomography of the orbit demonstrating a loss of globe contour&#x000a0;indicates severe trauma with possibly irreversible damage, suggesting a limited potential for meaningful visual recovery.</p>
      </sec>
      <sec id="article-133076.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>A meta-analysis of medical futility suggests that physicians are ultimately in charge of determining when care is futile. The literature has presented various approaches to measuring futility&#x000a0;and that&#x000a0;joint-decision making with the patient is preferred.<xref ref-type="bibr" rid="article-133076.r25">[25]</xref>&#x000a0;Important factors to utilize when making decisions include who will decide on futile care,&#x000a0;possible&#x000a0;treatment options, the goal of treatment, and the likelihood of achieving&#x000a0;said goal.<xref ref-type="bibr" rid="article-133076.r26">[26]</xref> In many conditions, it is very challenging to quantify likelihood as there is a shortage of literature describing end-stage diseases. Regardless, it is the physician's responsibility to help the patient and family understand all these factors about the care the patient is to receive.</p>
        <p>Therapeutic intervention can be considered for patients with complete visual loss and persistent eye pain.&#x000a0;Retrobulbar alcohol can be utilized to achieve pain control in blind painful eyes. Alcohol destroys the long and short posterior ciliary nerves, preventing pain signal transmission. One retrospective review reported 85% of patients were pain-free after receiving retrobulbar anesthesia, and&#x000a0;no patients&#x000a0;suffered adverse side effects.<xref ref-type="bibr" rid="article-133076.r27">[27]</xref>&#x000a0;Retrobulbar alcohol is a beneficial therapy in a patient&#x000a0;with painful&#x000a0;blindness who is not psychologically ready for an enucleation or evisceration procedure.&#x000a0;Retrobulbar alcohol may also effectively treat phantom pain syndrome after bilateral evisceration.<xref ref-type="bibr" rid="article-133076.r28">[28]</xref></p>
        <p>The Gunderson conjunctival flap surgically transposes conjunctivae to cover the cornea. This&#x000a0;procedure can help treat&#x000a0;herpetic keratitis, bullous keratopathy, neurotropic keratopathy, and traumatic relapsing keratopathy by decreasing pain from corneal surface injuries and preventing proteolytic enzymes from reaching the cornea.<xref ref-type="bibr" rid="article-133076.r29">[29]</xref>&#x000a0;However, amniotic membrane therapy has primarily replaced the conjunctival flap for non&#x02013;end-stage ocular conditions. Despite newer therapies, the conjunctival flap remains a helpful tool in&#x000a0;pain management for patients with severe corneal diseases who are not candidates for keratoplasty.&#x000a0;</p>
        <p>Permanent tarsorrhaphy can protect the eye from painful corneal exposure in situations where all other therapies have failed.<xref ref-type="bibr" rid="article-133076.r30">[30]</xref>&#x000a0;Evisceration or enucleation&#x000a0;can&#x000a0;be considered in patients with blind painful eyes, but not all patients have the healthy tenons and conjunctiva required for a successful surgery. A common cause of recurrence of pain after enucleation or evisceration involves dehiscence and exposure of the orbital implant.<xref ref-type="bibr" rid="article-133076.r31">[31]</xref></p>
        <p>Ethical considerations must be made when treating an eye with no light perception. Generally, surgical intervention in an eye with no visual potential is not recommended due to the increased risk of infection and sympathetic ophthalmia to the fellow-seeing eye.&#x000a0;Any intervention that could potentially impact the&#x000a0;better-seeing eye or the rest of the body must be approached with plenty of caution and restraint.</p>
        <p>However, cosmesis could be an indication to pursue surgery if significantly distressing to the patient. For example, leukocoria from a white cataract in an eye with no vision could warrant having a cataract evaluation if the patient has significant psychosocial stress from the appearance of the eye.<xref ref-type="bibr" rid="article-133076.r32">[32]</xref>&#x000a0;One study discussed&#x000a0;how job applicants with strabismus could be perceived as having less intelligence, aesthetic appeal, and more difficulty finding a job.<xref ref-type="bibr" rid="article-133076.r33">[33]</xref>&#x000a0;Thus, the cosmetic appearance of the eye should not be undervalued. There are other less invasive options than full cataract surgery for&#x000a0;blind patients with a white cataract, including colored contact lenses, corneal tattooing, and placement of a black sulcus lens.<xref ref-type="bibr" rid="article-133076.r34">[34]</xref><xref ref-type="bibr" rid="article-133076.r35">[35]</xref></p>
        <p>Another situation warranting consideration of incisional surgery is when the pain from the blind eye is caused by an easily modifiable problem such as a retained lens fragment. As always, when making this decision,&#x000a0;healthcare practitioners should strive to maintain patient autonomy, beneficence, and nonmaleficence. Pursuing an incisional intervention in a blind eye should only&#x000a0;occur after extensive discussion with the patient about their goals, the risks of the procedure, and possible alternative pursuits.</p>
      </sec>
      <sec id="article-133076.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>The following are examples of diseases that may lead to ocular futility:</bold>
</p>
        <p>
<bold>Advanced ARMD</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ocular histoplasmosis syndrome</p>
          </list-item>
          <list-item>
            <p>Myopic degeneration</p>
          </list-item>
          <list-item>
            <p>Choroidal rupture</p>
          </list-item>
          <list-item>
            <p>Angioid streaks</p>
          </list-item>
          <list-item>
            <p>Pattern dystrophy</p>
          </list-item>
          <list-item>
            <p>Drug toxicity&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Stargardt and other macular dystrophies</p>
          </list-item>
          <list-item>
            <p>Central serous chorioretinopathy</p>
          </list-item>
        </list>
        <p>
<bold>Strabismus in a Critically Ill Child</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Decompensated esotropias or exotropias</p>
          </list-item>
          <list-item>
            <p>Cranial nerve palsies</p>
          </list-item>
        </list>
        <p>
<bold>Advanced&#x000a0;Glaucoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Toxic or nutritional optic neuropathy</p>
          </list-item>
          <list-item>
            <p>Arteritic and non-arteritic ischemic optic neuropathies</p>
          </list-item>
          <list-item>
            <p>Traumatic optic neuropathy</p>
          </list-item>
          <list-item>
            <p>Compressive optic neuropathy</p>
          </list-item>
        </list>
        <p>
<bold>Neurotrophic Keratopathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dry eye</p>
          </list-item>
          <list-item>
            <p>Topical drug toxicity</p>
          </list-item>
          <list-item>
            <p>Exposure keratitis</p>
          </list-item>
          <list-item>
            <p>Contact lens-related disorders</p>
          </list-item>
          <list-item>
            <p>Chemical injury</p>
          </list-item>
          <list-item>
            <p>Limbal stem cell deficiency</p>
          </list-item>
          <list-item>
            <p>Acanthamoeba keratitis</p>
          </list-item>
          <list-item>
            <p>Herpetic keratitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-133076.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Ocular futility can only be considered in patients with a terminal prognosis from either an ocular condition or a systemic&#x000a0;disease that precludes further ocular therapy.</p>
      </sec>
      <sec id="article-133076.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Treating patients that could be deemed ocularly futile puts them at risk of complications from an intervention.</p>
        <p>Repeat intravitreal anti-VEGF injections for patients with advanced ARMD can lead to endophthalmitis, although the occurrence is rare and has been reported as 1 case per 2578 injections.<xref ref-type="bibr" rid="article-133076.r36">[36]</xref>&#x000a0;Eviscerations and enucleations also have many risks; a retrospective case series reported a reoperation risk of 14%.<xref ref-type="bibr" rid="article-133076.r37">[37]</xref>&#x000a0;Treating a patient with end-stage glaucoma with a trabeculectomy or drainage implant increases their risk of&#x000a0;infection to approximately 3%.<xref ref-type="bibr" rid="article-133076.r38">[38]</xref>&#x000a0;Other vision-threatening complications of these procedures include cataracts, hypotony, wound dehiscence, choroidal effusions, and procedure failure.<xref ref-type="bibr" rid="article-133076.r39">[39]</xref></p>
      </sec>
      <sec id="article-133076.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is a critical&#x000a0;intervention for ocular futility. Understanding their visual prognosis and the predicted benefits and associated risks of treatment&#x000a0;is&#x000a0;essential for patients to comprehend the futility of their care.</p>
      </sec>
      <sec id="article-133076.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ocular futility is challenging to identify and communicate with patients and their caregivers. There are no clear guidelines in the literature stating when further treatment is futile for different ocular diseases. Communication is paramount when&#x000a0;deciding that additional care is futile. The American Medical Association Code of Ethics offers a stepwise approach to discussing futile medical care with patients; this approach is not specific to ophthalmology or ocular futility.</p>
        <list list-type="order">
          <list-item>
            <p>Determine the goals of the patients and their caregivers to avoid miscommunication.</p>
          </list-item>
          <list-item>
            <p>Ensure that the patient and their caregivers receive all appropriate treatment if requested.</p>
          </list-item>
          <list-item>
            <p>Discuss a plan that achieves goals.</p>
          </list-item>
          <list-item>
            <p>If futile care continues to be requested, consider involving the institutional ethics committee.</p>
          </list-item>
          <list-item>
            <p>If no resolution can be achieved, consider transfer to another institution or&#x000a0;healthcare practitioner.&#x000a0;</p>
          </list-item>
        </list>
        <p>The&#x000a0;American Academy of Ophthalmology (AAO) Code of Ethics&#x000a0;states that it is unethical to recommend unnecessary treatment or withhold necessary treatment.&#x000a0;However, no specific guidelines are provided by the AAO in managing ocular futility. Therefore, it is recommended that&#x000a0;the following general principles are&#x000a0;applied in challenging ophthalmologic pathology that could be deemed futile.</p>
        <list list-type="bullet">
          <list-item>
            <p>Collaborate with&#x000a0;the patient, caregivers, and other&#x000a0;healthcare practitioners.</p>
          </list-item>
          <list-item>
            <p>Physician opinion can be highly influential on patients and caregivers. It is recommended that before deeming a situation futile, the practitioner remains open to other treatment options. These can be identified via discussions with the patient, caregivers, and colleagues and a literature review.</p>
          </list-item>
          <list-item>
            <p>The goal should be to achieve joint-decision making with the patient. All treatment information should be provided honestly and without bias so the patient and&#x000a0;caregivers can help steer the plan.</p>
          </list-item>
          <list-item>
            <p>The patient and their caregivers should be treated with respect and cultural humility.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>False hope should not be provided; instead, unbiased facts are preferred.</p>
          </list-item>
          <list-item>
            <p>If an agreement about a treatment plan cannot be made, there is no obligation to provide futile care. The ethical principles of beneficence and nonmaleficence are paramount. If absolutely necessary, the patient can be referred to another healthcare practitioner.</p>
          </list-item>
        </list>
        <p>The practitioner should never forget that pain relief and cosmesis are essential considerations when considering the overall quality of life in situations where vision cannot be saved.<xref ref-type="bibr" rid="article-133076.r26">[26]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-133076.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=133076&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=133076">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/ocular-futility-and-end-of-sight-care/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=133076">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/133076/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=133076">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-133076.s15">
        <title>References</title>
        <ref id="article-133076.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pina Mar&#x000ed;n</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gajate Paniagua</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Bald&#x000f3;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gallego-Pinazo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>385</fpage>
            <page-range>385-394</page-range>
            <pub-id pub-id-type="pmid">33719641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maisiak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mester</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Witherspoon</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>The Ocular Trauma Score (OTS).</article-title>
            <source>Ophthalmol Clin North Am</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-5, vi</page-range>
            <pub-id pub-id-type="pmid">12229231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colyer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Weichel</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Perforating globe injuries during operation Iraqi Freedom.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>115</volume>
            <issue>11</issue>
            <fpage>2087</fpage>
            <page-range>2087-93</page-range>
            <pub-id pub-id-type="pmid">18672293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Maino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Devadason</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leatherbarrow</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Open globe injuries: factors predictive of poor outcome.</article-title>
            <source>Eye (Lond)</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>1336</fpage>
            <page-range>1336-41</page-range>
            <pub-id pub-id-type="pmid">16179934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleckenstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>TDL</given-names>
              </name>
              <name>
                <surname>Guymer</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Chakravarthy</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schmitz-Valckenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klaver</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>Age-related macular degeneration.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2021</year>
            <month>May</month>
            <day>06</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">33958600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garweg</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Traine</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Garweg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gerhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pfister</surname>
                <given-names>IB</given-names>
              </name>
            </person-group>
            <article-title>Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series.</article-title>
            <source>Eye (Lond)</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>862</fpage>
            <page-range>862-868</page-range>
            <pub-id pub-id-type="pmid">33941877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kothari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balankhe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gawade</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Toshnival</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of psychosocial and emotional consequences of childhood strabismus on the families from rural and urban India.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2009</year>
            <season>Jul-Aug</season>
            <volume>57</volume>
            <issue>4</issue>
            <fpage>285</fpage>
            <page-range>285-8</page-range>
            <pub-id pub-id-type="pmid">19574696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Archer</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Musch</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Wren</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Guire</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Del Monte</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Social and emotional impact of strabismus surgery on quality of life in children.</article-title>
            <source>J AAPOS</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <page-range>148-51</page-range>
            <pub-id pub-id-type="pmid">15838442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harrad</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rumsey</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The psychosocial benefits of corrective surgery for adults with strabismus.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>883</fpage>
            <page-range>883-8</page-range>
            <pub-id pub-id-type="pmid">16782950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frankel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Juengst</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Cosmetic surgery for a fatally ill infant.</article-title>
            <source>J Pediatr Ophthalmol Strabismus</source>
            <year>1991</year>
            <season>Sep-Oct</season>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>250</fpage>
            <page-range>250-4</page-range>
            <pub-id pub-id-type="pmid">1955958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gandhewar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma.</article-title>
            <source>Eye (Lond)</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>936</fpage>
            <page-range>936-40</page-range>
            <pub-id pub-id-type="pmid">16628239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pokroy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Greenwald</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bukelman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zalish</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Visual loss after transscleral diode laser cyclophotocoagulation for primary open-angle and neovascular glaucoma.</article-title>
            <source>Ophthalmic Surg Lasers Imaging</source>
            <year>2008</year>
            <season>Jan-Feb</season>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-9</page-range>
            <pub-id pub-id-type="pmid">18254347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heijl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leske</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hussein</surname>
                <given-names>M</given-names>
              </name>
              <collab>Early Manifest Glaucoma Trial Group</collab>
            </person-group>
            <article-title>Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>10</issue>
            <fpage>1268</fpage>
            <page-range>1268-79</page-range>
            <pub-id pub-id-type="pmid">12365904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kass</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Heuer</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Higginbotham</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Keltner</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Parrish</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>120</volume>
            <issue>6</issue>
            <fpage>701</fpage>
            <page-range>701-13; discussion 829-30</page-range>
            <pub-id pub-id-type="pmid">12049574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <article-title>Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>126</volume>
            <issue>4</issue>
            <fpage>487</fpage>
            <page-range>487-97</page-range>
            <pub-id pub-id-type="pmid">9780093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Versura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giannaccare</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pellegrini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sebastiani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Neurotrophic keratitis: current challenges and future prospects.</article-title>
            <source>Eye Brain</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">29988739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosar</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rapuano</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Maus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penne</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Laibson</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Tarsorrhaphy: clinical experience from a cornea practice.</article-title>
            <source>Cornea</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>787</fpage>
            <page-range>787-91</page-range>
            <pub-id pub-id-type="pmid">11685052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terzis</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Dryer</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bodner</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Corneal neurotization: a novel solution to neurotrophic keratopathy.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-120</page-range>
            <pub-id pub-id-type="pmid">19116544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloch</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Munch</surname>
                <given-names>IC</given-names>
              </name>
            </person-group>
            <article-title>Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>153</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-213.e2</page-range>
            <pub-id pub-id-type="pmid">22264944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuhn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Witherspoon</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of blinding trauma in the United States Eye Injury Registry.</article-title>
            <source>Ophthalmic Epidemiol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-16</page-range>
            <pub-id pub-id-type="pmid">16854775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Ninan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Descriptive study on ocular survival, visual outcome and prognostic factors in open globe injuries.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2010</year>
            <season>Jul-Aug</season>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-3</page-range>
            <pub-id pub-id-type="pmid">20534923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Broman</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>The number of people with glaucoma worldwide in 2010 and 2020.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>262</fpage>
            <page-range>262-7</page-range>
            <pub-id pub-id-type="pmid">16488940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heijl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oskarsdottir</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and severity of undetected manifest glaucoma: results from the early manifest glaucoma trial screening.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>120</volume>
            <issue>8</issue>
            <fpage>1541</fpage>
            <page-range>1541-5</page-range>
            <pub-id pub-id-type="pmid">23631945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dierse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holtmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Geerling</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>260</volume>
            <issue>6</issue>
            <fpage>1961</fpage>
            <page-range>1961-1973</page-range>
            <pub-id pub-id-type="pmid">34989864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;fmark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nilstun</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Conditions and consequences of medical futility--from a literature review to a clinical model.</article-title>
            <source>J Med Ethics</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-9</page-range>
            <pub-id pub-id-type="pmid">11934942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Justin</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Rapuano</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Pelton</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Auran</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Ocular Futility: How to Approach End-of-Sight Care.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>126</volume>
            <issue>9</issue>
            <fpage>1209</fpage>
            <page-range>1209-1211</page-range>
            <pub-id pub-id-type="pmid">31443782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Narayanadas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Faruk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hafez</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Retrobulbar alcohol injection: A forgotten therapy for management of painful blind eye.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2018</year>
            <season>May-Aug</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-191</page-range>
            <pub-id pub-id-type="pmid">29930463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaichandran</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Bhaskar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Retrobulbar alcohol injection for phantom eye pain syndrome in bilateral eviscerated orbit.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2017</year>
            <season>Sep-Dec</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>264</fpage>
            <page-range>264-265</page-range>
            <pub-id pub-id-type="pmid">29118516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gundersen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pearlson</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Conjunctival flaps for corneal disease: their usefulness and complications.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1969</year>
            <volume>67</volume>
            <fpage>78</fpage>
            <page-range>78-95</page-range>
            <pub-id pub-id-type="pmid">5381310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Performing a tarsorrhaphy.</article-title>
            <source>Community Eye Health</source>
            <year>2015</year>
            <volume>28</volume>
            <issue>89</issue>
            <fpage>10</fpage>
            <page-range>10-1</page-range>
            <pub-id pub-id-type="pmid">26435586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah-Desai</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Tyers</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Manners</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Painful blind eye: efficacy of enucleation and evisceration in resolving ocular pain.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>84</volume>
            <issue>4</issue>
            <fpage>437</fpage>
            <page-range>437-8</page-range>
            <pub-id pub-id-type="pmid">10729307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schuman</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Ethical Considerations for Performing Intraocular Surgery on Eyes with No Light Perception.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-12</page-range>
            <pub-id pub-id-type="pmid">30577906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mojon-Azzi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mojon</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Strabismus and employment: the opinion of headhunters.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>87</volume>
            <issue>7</issue>
            <fpage>784</fpage>
            <page-range>784-8</page-range>
            <pub-id pub-id-type="pmid">18976309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alio</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sirerol</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walewska-Szafran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miranda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Corneal tattooing (keratopigmentation) with new mineral micronised pigments to restore cosmetic appearance in severely impaired eyes.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-9</page-range>
            <pub-id pub-id-type="pmid">19679571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aslam</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>MacLaren</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Unsutured phakic implantation of a black intraocular lens in the sulcus to treat leukocoria.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>40</volume>
            <issue>9</issue>
            <fpage>1565</fpage>
            <page-range>1565-7</page-range>
            <pub-id pub-id-type="pmid">25135551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres-Costa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brand&#x000e3;o</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carneiro</surname>
                <given-names>&#x000c2;</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rocha-Sousa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o-Reis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>600</fpage>
            <page-range>600-606</page-range>
            <pub-id pub-id-type="pmid">32019339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhoekx</surname>
                <given-names>JSN</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>WHW</given-names>
              </name>
              <name>
                <surname>Rengifo Coolman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Kinderen</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Wubbels</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Paridaens</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Complications Following Enucleations and Subsequent Oculoplastic Surgeries.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2018</year>
            <season>Jul/Aug</season>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>320</fpage>
            <page-range>320-323</page-range>
            <pub-id pub-id-type="pmid">28749852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaziri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kishor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Maharaj</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Moshfeghi</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Moshfeghi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Incidence of bleb-associated endophthalmitis in the United States.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>317</fpage>
            <page-range>317-22</page-range>
            <pub-id pub-id-type="pmid">25709395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-133076.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramona</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Monica</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Paul-Eduard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Speranta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calin-Petru</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative and postoperative complications in trabeculectomy, Clinical study.</article-title>
            <source>Rom J Ophthalmol</source>
            <year>2015</year>
            <season>Oct-Dec</season>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-247</page-range>
            <pub-id pub-id-type="pmid">29450314</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
